中国临床医学2024，Vol.31Issue(3)：374-378,5.DOI:10.12025/j.issn.1008-6358.2024.20240603
卡维地洛防治肝硬化门静脉高压研究进展
Research progress on the application of carvedilol in the treatment and prevention of portal hypertension in cirrhosis patients
摘要
Abstract
Cirrhosis is a severe disease caused by chronic inflammatory damage to the liver due to various factors,often complicated by portal hypertension.The primary causes of portal hypertension include increased intrahepatic vascular resistance and increased portal venous blood flow.Carvedilol,a third-generation non-selective beta-blocker(NSBB)with alpha-1 receptor-blocking role,is superior to traditional NSBBs in reducing portal pressure.It is believed that carvedilol significantly reduces hepatic venous pressure gradient(HVPG)through multiple mechanisms,prevents variceal bleeding,and extends patient survival.This paper reviews the mechanisms and clinical applications of carvedilol in the treatment of portal hypertension,focusing on its efficacy in the primary and secondary prevention of varices and its impact on the survival of cirrhotic patients with refractory ascites.关键词
卡维地洛/肝硬化/门静脉高压/食管胃静脉曲张Key words
carvedilol/cirrhosis/portal hypertension/esophagogastric varices分类
医药卫生引用本文复制引用
程雅玮,朱晓龙,张春清..卡维地洛防治肝硬化门静脉高压研究进展[J].中国临床医学,2024,31(3):374-378,5.基金项目
国家自然科学基金(81970533,81770606).Supported by National Natural Science Foundation of China(81970533,81770606). （81970533,81770606）
